Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives
Open Access
- 19 October 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 209, 107469
Abstract
No abstract availableKeywords
This publication has 125 references indexed in Scilit:
- Chemical Biology Approaches toward Precise Structure Control of IgG‐Based Antibody‐Oligonucleotide ConjugatesChemBioChem, 2023
- RNAi-based therapeutics and tumor targeted delivery in cancerAdvanced Drug Delivery Reviews, 2022
- Detection and destruction of HER2‐positive cancer cells by Ultra Quenchbody‐siRNA complexBiotechnology and Bioengineering, 2020
- Strategies, design, and chemistry in siRNA delivery systemsAdvanced Drug Delivery Reviews, 2019
- Antibody‐drug therapeutic conjugates: Potential of antibody‐siRNAs in cancer therapyJournal of Cellular Physiology, 2019
- Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug ConjugatesBioDrugs, 2018
- Using Morpholinos to Control Gene ExpressionCurrent Protocols in Nucleic Acid Chemistry, 2017
- Functional peptides for siRNA deliveryAdvanced Drug Delivery Reviews, 2017
- Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotidesAdvanced Drug Delivery Reviews, 2015
- Specificity, polyspecificity, and heterospecificity of antibody‐antigen recognitionJournal of Molecular Recognition, 2014